NCT05933265 - Study of LP-184 in Patients With Advanced Solid Tumors | Biotech Hunter

Enrollment

175

Participants

Timeline

Start Date

June 9, 2023

Primary Completion Date

February 28, 2025

Study Completion Date

September 9, 2025

Conditions

Advanced Solid TumorMetastatic Solid TumorGBMTNBC - Triple-Negative Breast CancerNSCLCPancreatic AdenocarcinomaDDR Gene Mutation

Interventions

DRUG

LP-184

LP-184 is a small molecule alkylating agent causing tumor cell death through DNA damage.

DRUG

Spironolactone

A competitive mineralocorticoid receptor antagonist that inhibits aldosterone-dependent sodium reabsorption/ potassium excretion and lowering blood pressure, as well as degrades the transcription coupled nucleotide excision repair protein ERCC3 to impair DNA repair.

DRUG

Olaparib

A poly (ADP-ribose) polymerase (PARP) inhibitor that impairs homologous recombination (HR) dependent DNA damage repair by trapping PARP1/2 on DNA, leading to synthetic lethality in BRCA1/2-deficient cells.

Trial Locations (9)

19111

RECRUITING

Fox Chase Cancer Center, Philadelphia

21287

RECRUITING

John Hopkins - The Sidney Kimmel Comprehensive Cancer Center, Baltimore

40205

RECRUITING

Norton Healthcare, Inc., Louisville

46202

RECRUITING

Indiana University Melvin and Bren Simon Cancer Center, Indianapolis

60008

RECRUITING

Northwest Oncology & Hematology, Rolling Meadows

72758

RECRUITING

Highlands Oncology Group, Springdale

78229

RECRUITING

UT Health Science Center San Antonio, San Antonio

84119

RECRUITING

START Mountain Region, West Valley City

90720

RECRUITING

Cancer and Blood Specialty Clinic, Los Alamitos